Biomedicine is still the "good heart" of institutional research, and these companies are favored.

Pharmaceutical Network Industry Dynamics The biopharmaceutical industry is regarded by many economists as a "sunrise industry that does not decline".from the development trend of the world biopharmaceutical industry, biomedicine is currently in the beginning of large-scale industrialization of technology, it is expected that 2020 will enter a period of rapid development, and gradually become the leading industry of the world economy.the biopharmaceutical industry is highly sought after, it is understood that many recently many biopharmaceutical enterprises by the institutions pile up research.Biomedicine is still the institutional research "good heart" (picture source: pharmaceutical network) Lizhu Group from a stock point of view, Lizhu Group is favored by institutions.statistics, in the past five trading days, Lizhu Group was investigated by 151 institutions.includes 53 private placements, 31 fund companies, 34 securities companies, 5 insurance companies and 28 capital management companies.notable, The Group has gained nearly 60 per cent since March and its share price hit a record high last week.'s microball business is one of the concerns that attracts many institutional concerns.according to the company's relevant person in charge of the introduction, microsphere is a high barrier drug, the current collection of microspheres for the time being no big impact.from the perspective of industrialization, microsphere platform experienced nearly 10 years of accumulated technical experience, the current industrialization problem is not too big.in recent years Lizhu has been accelerating the pace of microsphere development, production lines have been in the production of clinical drugs, research and development speed gradually improved.the statistics of Kanghong Pharmaceuticals, Kanghong Pharmaceuticals has welcomed a total of 61 institutional research, including 9 private placements, 38 fund companies, 4 securities companies, 1 insurance company, and 9 management companies.it is understood that Kanghong pharmaceutical products CompaqIp eye injection (commodity name: Long Mu) with multi-target, affinity and strong advantages, drug economics advantages are obvious;shuanglin biological data statistics, Shuanglin bio-survey of 46 institutions, including 7 private placements, 14 fund companies, 16 securities companies, 9 capital management companies.Shuanglin Bio is a collection of blood products research and development, production and sales as one of the high-tech enterprises, but also China's first batch through the national GMP certification of blood products fixed-point production enterprises.listed companies have a total of 17 wholly-owned and controlled subsidiaries, Guangdong Shuanglin Biopharmaceutical Co., Ltd. as its core enterprises. Shuanglin Biology is mainly engaged in the blood products industry. as of March 31, 2020, its operating income was RMB210.49 million, and net income attributable to shareholders of the parent company was RMB2498.6719 million, an increase of 2.6405 percent year-on-year, with basic earnings per share of RMB0.0917. Xingqi eye drug statistics, Xingqi eye medicine a total of 42 institutional research, including 11 private placement, 16 fund companies, 9 securities companies, 6 management companies. Xingqi eye medicine in the research pointed out that the company in 2018, 2019 research and development investment accounted for about 10% of sales revenue, the future will continue to increase investment in research and development, only in the high investment in research and development, later in the emergence of more new products, in order to maintain sustainable development of enterprises. company in OK mirror and other product development will take the model of imitation combination. recently approved the 0.05% cyclosporine eye drops (II), the company believes that the future of the product is a competitive product. at the beginning of the market, Xingqi eye medicine will focus the use of products in patients with moderate to severe dry eye and immune disease-related dry eyes, accurately target patients, and through a variety of medical and market projects to promote the treatment of standardized treatment. .